Celltrion Earnings Jump Shows Stronger Growth Potential Celltrion is rated Buy as analysts expect upside; latest quarter shows revenue +36% YoY but operating profit +115% and net profit +219%, driven by U.S. biosimilar expansion. 2026년 07월 23일 English
